Citation:Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, et al 2011

From Cancer Guidelines Wiki

Citation


Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011 Jul;22(7):1535-46 Available from: http://www.ncbi.nlm.nih.gov/pubmed/21228335.



Critical appraisals

Critical appraisal linkClinical questionAssigned toStatus
Optimal molecular profilingVictoria Freemancompleted
Optimal molecular profilingBen Lee-Batescompleted

Compare quality appraisals for each clinical question

  • [[Clinical question:Molecular profiling of CRC|
    Invalid title «<span class="smw-format list-format "><span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:Molecular profiling of CRC</span></span></span>»
    ]] (compare critical appraisals)
  • [[Clinical question:Molecular profiling of CRC|
    Invalid title «<span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:Molecular profiling of CRC</span></span></span></span>»
    ]] (compare critical appraisals)

Cited by

  1. Molecular pathology and biomarkers – implications for systemic therapy
  2. Optimal molecular profiling
  3. Role of biological agents in first-line treatment of metastatic colorectal cancer
  4. Systemic chemotherapy treatment options for first-line treatment